You are here: Home » Companies » News
Business Standard

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established

Topics
Pharma Companies | Indian pharma companies | Medicines

Sohini Das & Ruchika Chitravanshi  |  Mumbai/New Delhi 

drug, medicine, pharmaceutical, pharma
Annual sales of Iverm­ectin were around Rs 19 crore in 2018 and went up to Rs 21 crore in 2019. In 2020 it shot up to Rs 94 crore

Ivermectin, a drug used to treat parasitic infections, rose to prominence in 2020 as a treatment for Covid-19, pushing its sales up by more than 25 times, prompting more drug firms to launch the product.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, February 06 2021. 06:10 IST
RECOMMENDED FOR YOU
.